Daniel G. Coit, MD, FACS
Surgical Oncologist
Titles
Attending Surgeon
Clinical Expertise
General Surgical Oncology; Melanoma; Sarcoma; Pancreatic Cancer; Gastric Cancer
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Coit accepts the following list of insurance providers. Select your insurance provider to see more details.
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO, DSN
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO EPO
Payor Type: Commercial
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): Federal Government
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP
Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): TBD
Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO
Payor Type: Commercial
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Contact and Location
- 212-639-8411 Office Phone
- Speaks English
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
See all locationsAbout Me
Education
MD, University of Cincinnati
Residencies
Surgery - New England Deaconess Hospital; Surgery - Aberdeen Royal Infirmary; Surgery - New England Deaconess Hospital
Fellowships
Surgery - Memorial Sloan Kettering Cancer Center
Board Certifications
Surgery
I am a surgical oncologist whose primary area of clinical and research interest is melanoma. In 1991, I introduced lymph-node mapping and sentinel lymph-node biopsy for melanoma and other selected skin cancers. Together, these procedures can determine during surgery whether a tumor has spread to surrounding lymph nodes. Using lymph node mapping, we can pinpoint the precise lymph node into which a nearby tumor is likely to travel first (called the sentinel node). If a biopsy of the sentinel node indicates cancer spread, the surrounding lymph nodes are removed. But if there is no evidence of cancer in the sentinel node, patients are spared from additional lymph node surgery.
Read more
My research has focused primarily on detecting and defining the clinical significance of individual melanoma cells in the sentinel lymph nodes, blood, and bone marrow of melanoma patients, with the goal of identifying patients at highest risk of cancer recurrence following surgery to remove a melanoma.
I served as Chief of the Gastric and Mixed Tumor Service in Memorial Sloan Kettering’s Department of Surgery from 1997 until October 2003. This service focuses primarily on the surgical management of less common malignancies, including melanoma, sarcoma, gastric cancer, and pancreatic cancer, and also provides surgical support for the Lymphoma Service.
I currently serve as a co-leader of the Melanoma Disease Management Team — a multidisciplinary team of surgeons, medical oncologists, pathologists, and other medical professionals at Memorial Sloan Kettering who specialize in the diagnosis and treatment of melanoma. On a national and international level, I am involved in advancing new ways to diagnose and treat melanoma as a member of the American Joint Commission on Cancer Melanoma Staging Committee, the National Comprehensive Cancer Network Melanoma Advisory Group, the American College of Surgeons Commission on Cancer Melanoma Working Group, the American College of Surgeons Oncology Group’s Melanoma Working Group, and the World Health Organization Melanoma Committee.
In addition to my interest in melanoma, I also have an expertise in the treatment of gastric cancer. I served on the program committee of the International Gastric Cancer National Meeting in 2001. And in 2002, I was co-leader of the Gastric Cancer Working Group of the National Cancer Institute’s Stomach Cancer Progress Review Group. I am currently the co-principal investigator of two gastric cancer studies at Memorial Sloan Kettering. The first evaluates the effectiveness of chemotherapy prior to surgery in high-risk gastric cancer patients, and the second is a “Quality of Life Assessment” of gastric cancer patients. I am also an active member of the American College of Surgeons Oncology Group Upper GI Cancer Working Group.
Memorial Sloan Kettering Cancer Center plays a key role in training oncology doctors, and I have had a long-standing interest in the training of surgical oncology fellows. I served as the Director of Surgical Education for the Surgical Oncology Fellowship Training Program at Memorial Sloan Kettering from 1991 to 1997, and I was Director of the Society of Surgical Oncology Training Committee, where I oversaw the administration of all surgical oncology fellowships across the nation from 1994 to 1999.
As part of my interest in spreading information we have learned about cancer at Memorial Sloan Kettering, I have lectured extensively, both nationally and internationally, and authored a number of manuscripts and reviews on various surgical oncology topics.
Awards and Honors
- Castle Connolly: America's Top Doctors (2023)
- Castle Connolly: New York Magazine Top Doctors (2002-2020)
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Book Chapters
“Technique of hyperthermic isolation limb perfusion.” Coit DG. In: Atlas of Surgical Oncology. Monson JRT, Donohue JH, van Heerden JA, eds. Oxford: Blackwell Scientific ; 1995: 45-49.
“Malignant melanoma.” Coit DG: In: Conn’s Current Therapy. Rakel RE, ed. Philadelphia: WB Saunders; 1997: 818-820.
“Isolated perfusion of extremity tumors.” Fraker D, Coit DG. In: Regional Therapy of Advanced Cancer. Lotze M et. al, eds. Philadelphia: Lippincott-Raven; 1997: 333-349.
Read more
“Regional chemotherapy of melanoma.” Brady MS, Coit DG. In: Regional Chemotherapy Clinical Research and Practice. Markman M, ed. Totowa, NJ: Humana Press; 2000: 33-55.
“Cancer of the small intestine.” Coit DG. In: Cancer: Principles and Practice of Oncology. 6th ed. DeVita VT, Hellman S, Rosenberg SA, eds. Philadelphia: Lippincott-Raven; 2001: 1204-1215.
“Technique of lymphatic mapping with sentinel lymph node biopsy in patients with malignant melanoma.” Coit DG. In: Sentinel Lymph Node Biopsy. Cody H., ed. London: Martin Dunitz; 2002:135-142.
“Metastatic surveillance and follow-up.” Coit DG, Ferrone CR. In: Cutaneous Melanoma. 4th ed. Balch CM, Houghton AN, Sober AJ, Soong, SJ, eds. St. Louis: Quality Medical Publishing; 2003: 511-521.
“Metastatic melanoma at distant sites — followup.” Olsen J, Coit DG. In: Textbook of Melanoma. Thompson J, Morton D, Kroon B., eds. London: Martin Dunitz; 2004: 449-458.
“Inguinofemoral, iliac/obturator, and popliteal lymphadenectomy in patients with melanoma.” Jacobs LK, Balch CM, Coit DG: In: Cutaneous Melanoma. 5th ed. Balch CM, Houghton AN, Sober AJ, Soong, SJ, Atkins MB, Thompson JF, eds. St. Louis: Quality Medical Publishing; 2009.
“Recurrent regional metastases of melanoma.” Coit DG, Ferrone CR. In: Cutaneous Melanoma. 5th ed. Balch CM, Houghton AN, Sober AJ, Soong, SJ, Atkins MB, Thompson JF eds. St. Louis: Quality Medical Publishing; 2009.
“Radical groin dissection.” Coit DG. In: Mastery of Surgery. Fischer J, eds. Philadelphia: Lippincott Williams and Wilkins; 2012: 1743-57.
Visit PubMed for a full listing of Dr. Coit’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Daniel G. Coit discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
